Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).
Abroad (travel likely)RecruitingPHASE1, PHASE2
Conditions
Solid Tumor Cancer · Medulloblastoma · High Risk Neuroblastoma · High Grade Gliomas · Meningioma · Paraganglioma · Pheochromocytoma · Neuroendocrine Tumours (NET) · Adrenal Tumours · DIPG · Glioblastoma · Glioblastoma (GBM) · Osteosarcoma Recurrent · Carcinoma Adrenal · Synovial Sarcomas · Esthesioneuroblastoma · Neuroblastoma Recurrent · Solid Tumor Refractory to Conventional Treatment · Medulloblastoma Recurrent · Paraganglioma/ Phaeochromocytoma · Ependymoma · Ependymoma Recurrent
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
HM Monteprincipe, Boadilla del Monte, Madrid, Spain
Study leads
Marta Osuna Marco, PhD
Study Director
HM Monteprincipe